Biotech Startups Hoping to “Thrive” Amid Coronavirus Chaos

 In AlphaCentric, Articles, LifeSci Healthcare Fund

Drug startups raised $16.6 billion in venture capital last year, the second highest total for the decade behind the $18.6 billion they secured in 2018, according to PitchBook Data Inc. Last year, 50 biotechs went public, and the median pre-money valuation for biotech initial public offerings reached a record $337 million, according to Silicon Valley Bank.  The new Coronavirus forces small drugmakers to adapt.

Comments published March 31 2020 in the Wall Street Journal from the Portfolio Manager of AlphaCentric LifeSci Healthcare Fund, Dr. Mark Charest:

When new offerings resume, IPO hopefuls will face investor questions about their ability to operate in spite of the uncertainty, he added. “They’ll have to make a strong case as to why they can move their programs forward despite the changing environment,” Dr. Charest said.

Source: Wall Street Journal March 31 2020 – read the complete article here

More on the AlphaCentric LifeSci Healthcare Fund 

Recommended Posts

Leave a Comment

Contact Us

Have a question? We'd love to hear from you! Drop us a line and we'll respond to your inquiry ASAP!

Start typing and press Enter to search